← Back to Clinical Trials
Recruiting NCT06243978

NCT06243978 Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06243978
Status Recruiting
Phase
Sponsor Gaia AG
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 328 participants
Start Date 2024-04-02
Primary Completion 2025-04-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
liebriainformation brochure on hypertension

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 328 participants in total. It began in 2024-04-02 with a primary completion date of 2025-04-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial with 328 patients with primary hypertension aims to investigate the effectiveness of the self-guided digital application liebria for patients with primary hypertension.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 * Presence of primary hypertension, confirmed by submission of a medical certificate or equivalent (e.g., informal letter signed by primary care physician); relevant ICD-10-GM diagnoses: * I10.00 (Benign essential hypertension: Without indication of hypertensive crisis) * I10.90 (Essential hypertension, unspecified: Without indication of hypertensive crisis) * Unmedicated or with existing antihypertensive drug therapy (with stable dose in the past 6 weeks prior to study enrolment) * Last reported office-based systolic blood pressure (SBP) ≥ 140 mmHg followed by home-based SBP ≥ 135 mmHg * Consent to participate Exclusion Criteria: * Home-based SBP \> 180 mmHg * \> Triple combination of antihypertensive medication * History of secondary hypertension (e.g., thyroid disease, kidney disease) * Pregnancy

Contact & Investigator

Central Contact

Gitta A. Jacob, PhD

✉ gitta.jacob@gaia-group.com

📞 +49.40.349930-374

Principal Investigator

Kamila Jauch-Chara, MD

PRINCIPAL INVESTIGATOR

University Hospital Schleswig-Holstein

Frequently Asked Questions

Who can join the NCT06243978 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06243978 currently recruiting?

Yes, NCT06243978 is actively recruiting participants. Contact the research team at gitta.jacob@gaia-group.com for enrollment information.

Where is the NCT06243978 trial being conducted?

This trial is being conducted at Hamburg, Germany.

Who is sponsoring the NCT06243978 clinical trial?

NCT06243978 is sponsored by Gaia AG. The principal investigator is Kamila Jauch-Chara, MD at University Hospital Schleswig-Holstein. The trial plans to enroll 328 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology